Abstract：
BACKGROUND: In this cross-sectional study, we compared fasting serum asprosin levels and metabolic parameters between patients receiving one of three atypical antipsychotics (olanzapine, risperidone, or aripiprazole) and healthy subjects.
METHODS: The study population included 62 adult outpatients with schizophrenia and 22 healthy controls, matched for age and gender. Patients were in remission and had been on stable monotherapy with one of these atypical antipsychotics for over 6 months. Body Mass Index (BMI) and fasting serum levels of asprosin, glucose, HA1c, insulin, and lipid profile were compared across the investigated groups. Additionally, the number of participants meeting the insulin resistance criterion, defined as homeostasis model assessment for insulin resistance (HOMA-IR) >2.5, as well as the number of participants with elevated BMI levels (men >27 kg/m2, women >25 kg/m2) were compared among the groups.
RESULTS: We observed statistically significant differences in BMI and fasting serum levels of glucose, HA1c, insulin, triglyceride (TG), high-density lipoprotein cholesterol, and asprosin among patients receiving olanzapine or risperidone, as compared to those receiving aripiprazole and healthy subjects. Patients on aripiprazole exhibited values comparable to healthy subjects, whereas those on risperidone or olanzapine showed significantly higher values, with the highest observed in the olanzapine group. Additionally, the prevalence of participants meeting the insulin resistance criterion and those with elevated BMI was also greater in individuals receiving olanzapine or risperidone compared to those on aripiprazole and healthy subjects. Serum asprosin levels showed a significant positive correlation with BMI and several metabolic parameters, including HbA1c, fasting insulin, HOMA-IR, and TG. No significant differences were observed among the investigated groups in terms of serum levels of total cholesterol and low-density lipoprotein cholesterol.
CONCLUSIONS: Our cross-sectional study highlights the association between elevated asprosin levels, weight gain, and metabolic disorders in patients treated with olanzapine and risperidone. Given the bidirectional nature of the relationship between serum asprosin levels and these metabolic disturbances, further research is warranted to elucidate potential causative pathways.
METHODS: The study population included 62 adult outpatients with schizophrenia and 22 healthy controls, matched for age and gender. Patients were in remission and had been on stable monotherapy with one of these atypical antipsychotics for over 6 months. Body Mass Index (BMI) and fasting serum levels of asprosin, glucose, HA1c, insulin, and lipid profile were compared across the investigated groups. Additionally, the number of participants meeting the insulin resistance criterion, defined as homeostasis model assessment for insulin resistance (HOMA-IR) >2.5, as well as the number of participants with elevated BMI levels (men >27 kg/m2, women >25 kg/m2) were compared among the groups.
RESULTS: We observed statistically significant differences in BMI and fasting serum levels of glucose, HA1c, insulin, triglyceride (TG), high-density lipoprotein cholesterol, and asprosin among patients receiving olanzapine or risperidone, as compared to those receiving aripiprazole and healthy subjects. Patients on aripiprazole exhibited values comparable to healthy subjects, whereas those on risperidone or olanzapine showed significantly higher values, with the highest observed in the olanzapine group. Additionally, the prevalence of participants meeting the insulin resistance criterion and those with elevated BMI was also greater in individuals receiving olanzapine or risperidone compared to those on aripiprazole and healthy subjects. Serum asprosin levels showed a significant positive correlation with BMI and several metabolic parameters, including HbA1c, fasting insulin, HOMA-IR, and TG. No significant differences were observed among the investigated groups in terms of serum levels of total cholesterol and low-density lipoprotein cholesterol.
CONCLUSIONS: Our cross-sectional study highlights the association between elevated asprosin levels, weight gain, and metabolic disorders in patients treated with olanzapine and risperidone. Given the bidirectional nature of the relationship between serum asprosin levels and these metabolic disturbances, further research is warranted to elucidate potential causative pathways.
摘要：
背景：在这项横断面研究中，我们比较了接受三种非典型抗精神病药（奥氮平，利培酮,或阿立哌唑）和健康受试者。
方法：研究人群包括62名精神分裂症成年门诊患者和22名健康对照者，年龄和性别相匹配。患者处于缓解状态，并且使用这些非典型抗精神病药之一进行了稳定的单药治疗超过6个月。身体质量指数（BMI）和空腹血清水平，葡萄糖，HA1c,胰岛素，和血脂分布进行了比较。此外,符合胰岛素抵抗标准的参与者人数，定义为胰岛素抵抗(HOMA-IR)>2.5的稳态模型评估,并在各组间比较BMI水平升高(男性>27kg/m2,女性>25kg/m2)的参与者人数.
结果：我们观察到BMI和空腹血糖水平的统计学差异，HA1c,胰岛素，甘油三酯（TG），高密度脂蛋白胆固醇，在接受奥氮平或利培酮的患者中，与接受阿立哌唑和健康受试者相比。服用阿立哌唑的患者表现出与健康受试者相当的价值，而那些服用利培酮或奥氮平的药物显示出明显更高的价值，在奥氮平组中观察到的最高。此外,与阿立哌唑和健康受试者相比,在接受奥氮平或利培酮治疗的个体中,符合胰岛素抵抗标准和BMI升高者的患病率也更高.血清乙酰肝素水平与BMI和一些代谢参数呈显著正相关,包括HbA1c,空腹胰岛素，HOMA-IR,TG。在总胆固醇和低密度脂蛋白胆固醇的血清水平方面，研究组之间没有观察到显着差异。
结论：我们的横断面研究强调了升高的阿帕罗素水平之间的关联，体重增加,奥氮平和利培酮治疗的患者代谢紊乱。鉴于血清天门冬氨酸水平和这些代谢紊乱之间的关系的双向性质，需要进一步的研究来阐明潜在的致病途径.
方法：研究人群包括62名精神分裂症成年门诊患者和22名健康对照者，年龄和性别相匹配。患者处于缓解状态，并且使用这些非典型抗精神病药之一进行了稳定的单药治疗超过6个月。身体质量指数（BMI）和空腹血清水平，葡萄糖，HA1c,胰岛素，和血脂分布进行了比较。此外,符合胰岛素抵抗标准的参与者人数，定义为胰岛素抵抗(HOMA-IR)>2.5的稳态模型评估,并在各组间比较BMI水平升高(男性>27kg/m2,女性>25kg/m2)的参与者人数.
结果：我们观察到BMI和空腹血糖水平的统计学差异，HA1c,胰岛素，甘油三酯（TG），高密度脂蛋白胆固醇，在接受奥氮平或利培酮的患者中，与接受阿立哌唑和健康受试者相比。服用阿立哌唑的患者表现出与健康受试者相当的价值，而那些服用利培酮或奥氮平的药物显示出明显更高的价值，在奥氮平组中观察到的最高。此外,与阿立哌唑和健康受试者相比,在接受奥氮平或利培酮治疗的个体中,符合胰岛素抵抗标准和BMI升高者的患病率也更高.血清乙酰肝素水平与BMI和一些代谢参数呈显著正相关,包括HbA1c,空腹胰岛素，HOMA-IR,TG。在总胆固醇和低密度脂蛋白胆固醇的血清水平方面，研究组之间没有观察到显着差异。
结论：我们的横断面研究强调了升高的阿帕罗素水平之间的关联，体重增加,奥氮平和利培酮治疗的患者代谢紊乱。鉴于血清天门冬氨酸水平和这些代谢紊乱之间的关系的双向性质，需要进一步的研究来阐明潜在的致病途径.
